Top UK Facility Achieves Funding Success
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
Clinical researchers at St George’s, University of London, U.K. have used crowd-funding methods based on donations and rewards to raise cash for a Phase II trial in 140 bowel cancer patients on the FutSci platform.
The campaign has reached its target of £50,000 (approximately $75K) in the first 45 days, according to Dr Deepika Kassen, PhD, Director of FutSci. To date it has been backed by 320 people from 16 countries and has raised £53,088.88 ($80564.76). There are still 10 days left of the campaign.
Scientists plan to use the funds to repurpose Artesunate, an antimalarial drug discovered by Nobel Prize Laureate (2015) Tu Youyou, in a clinical trial aimed at cutting the rate of metastases in colorectal cancer.
The campaign is a collaboration between the researchers, FutSci, Bowel Disease UK and the Anticancer Fund. The researchers are using the money to top-up funds they already have from charity. Budget cuts mean the research is not funded by government/institutional bodies, and the pharmaceutical industry is not interested because it is a relatively cheap drug, noted Kassen.
More information is available at www.futsci.com/project/antimalarial-cancer.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
